Angiotech Pharma Acquires Product Candidates and
Technology Assets from Haemacure Corporation
Reference Code: GDME0012M&A Publication Date: April 2010
1 Table of Contents 2 Angiotech Pharma Acquires Product
1 Table of Contents ..........................................................1 Candidates and Technology Assets from
1.1 List of Tables ..........................................................1 Haemacure Corporation
1.2 List of Figures.........................................................1
2 Angiotech Pharma Acquires Product Candidates and 2.1 What is this Report About?
Technology Assets from Haemacure Corporation ................1
2.1 What is this Report About?.....................................1 GlobalData’s dedicated research and analysis team exhaustively
2.2 Deal Background....................................................1 researched and evaluated the acquisition of lead product
2.3 Deal Rationale........................................................2 candidates and technology assets of Haemacure Corporation by
2.4 The Acquired Products...........................................3 Angiotech Pharma. The rationale of the deal was evaluated by the
3 Appendix .......................................................................4
team, based on a close study of each of the company’s products,
3.1 Research Methodology ..........................................4
3.2 Coverage................................................................5 intellectual property and the general market trends, market
3.3 Secondary Research..............................................5 revenues in the wound care market in the US and Europe.
3.4 Primary Research...................................................5
3.5 Models....................................................................5 2.1.1 Deal Details
3.6 Forecasts ...............................................................5 Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a
3.7 Expert Panels .........................................................6 specialty pharmaceutical and medical device company, announced
3.8 GlobalData Consulting ...........................................6
the closing of its acquisition of certain product candidates and
3.9 Contact Us .............................................................6
3.10 Disclaimer..........................................................6 technology assets of Haemacure Corporation (“Haemacure”).
Haemacure has been involved in proceedings under Canada’s
Bankruptcy and Insolvency Act and Chapter 11 of the United
States Bankruptcy Code. Through an asset sale transaction,
1.1 List of Tables Angiotech has acquired all of the relevant research and
Table 1: Wound Closure Devices Market, Global, Revenue development activities, manufacturing operations, key personnel,
($m), 2009 – 2016 3 and intellectual property rights necessary to pursue the
Table 2: Hemaseel Thrombin Haemostatic Agent Product commercialization of Haemacure’s human biomaterial product
Details 4 candidates, namely, fibrin sealant and thrombin hemostat. The
Table 3: Hemaseel HMN fibrin sealant-Adhesion Prevention,
Product Details 4 proprietary fibrin sealant is made of two human plasma proteins,
Table 4: Hemaseel HMN fibrin sealant-Hemostatis, Product fibrinogen and thrombin, which are extracted from human blood
Details 4 plasma through a proprietary, high-yield, low-cost extraction
process.
1.2 List of Figures 2.2 Deal Background
Figure 1: Wound Closure Market, Global, Revenue ($m), Angiotech Pharmaceuticals, Inc. in 2009 made a collaborative
2009 – 2016 2 transaction with Haemacure Corporation related to Haemacure’s
Figure 2: GlobalData Methodology 4
proprietary fibrin and thrombin technologies, both of which are
currently in development. As part of this collaboration, Angiotech
had agreed to provide to Haemacure a senior secured bridge
financing facility of US$2.5 million, with the option for Angiotech to
invest an additional US$1 million in the facility. The collabor